Triazavirin capsules 250mg, 10pcs

Composition

Active ingredient: methylthionitrooxodihydrotriazolotriazinide sodium dihydrate (triazavirin®) – 250 mgsupport substances: Calcium stearate – 2 mgmass of capsule contents-252 mgcomposition of capsule shell: Capsule (body) No. 1: titanium dioxide (E 171), yellow quinoline (E 104), yellow “sunny sunset” (E 110), medical gelatin. Capsule (cap) No. 1: titanium dioxide (E 171), azorubin (E 122), medical gelatin. Capsule weight with contents-328 mg

Pharmacological action

Pharmacotherapeutic group: Antiviral agent ATX code: J05axpharmacological Propertiespharmacodynamicthe Active ingredient of the drug Triazavirin® is a synthetic analog of purine nucleoside bases (guanine) with a pronounced antiviral effect. It has a wide spectrum of antiviral activity against RNA-containing viruses. The main mechanism of action of Triazavirin® is inhibition of viral RNA synthesis and replication of genomic fragments. Pharmacokineticsafter oral use, it is rapidly absorbed in the gastrointestinal tract. The maximum concentration (Cmax) is reached on average after 1-1.5 hours. Cmax with the recommended dosage regimen averages 4.8 mcg / ml. The AUC (area under the concentration – time pharmacokinetic curve) of blood is 12.8 mcg / h * ml. The half-life (T1 / 2) is 1-1.5 hours. The kidneys in unchanged form are excreted from 15 to 45% of methylthionitrooxodihydrotriazolotriazinide sodium. The average calculated clearance is 246 ml/min.

Indications

As part of the complex therapy of influenza in adult patients.

Use during pregnancy and lactation

Due to the lack of strictly controlled studies in humans, the use of the drug during pregnancy is contraindicated (see the section “Contraindications”). The use of the drug during breastfeeding has not been studied, so if it is necessary to use the drug during lactation, breastfeeding should be discontinued.

Contraindications

-hypersensitivity to the components of the drug;— pregnancy; – breast-feeding period; – children under 18 years of age (efficacy and safety have not been determined);— renal / hepatic insufficiency (efficacy and safety have not been determined).

Side effects

Allergic reactions. From the digestive system-dyspeptic disorders (flatulence, diarrhea, nausea, vomiting).

Interaction

Interaction with analogues of purine and pyrimidine bases during antitumor therapy may lead to increased toxicity of the drug. When used concomitantly with ribavirin, a reduction in the dose of ribavirin is required.

How to take, course of use and dosage

Triazavirin® is taken orally regardless of food intake, washed down with a sufficient amount of drinking water. The capsule should be swallowed whole, it is not recommended to chew or crush the capsule. Taking the drug should be started no later than the 2nd day after the onset of the disease (the appearance of clinical symptoms of influenza). The recommended dose is 1 capsule (250 mg) 3 times daily for 5 consecutive days. If necessary, on the recommendation of a doctor, treatment can be continued for up to 7 days. The maximum daily dose is 3 capsules (750 mg).

Overdose

Symptoms: nausea, vomiting, dyspeptic disorders, stomach pain. Treatment: symptomatic therapy. If these symptoms occur, you should stop taking the drug and consult a doctor.

Special instructions

The effect of the drug on the ability to drive vehicles has not been studied, however, based on the spectrum of adverse reactions, no effect on these activities is expected.

Storage conditions

In a dark place at a temperature not exceeding 25°C. Keep out of reach of children.

Shelf

life is 5 years. Do not use after the expiration date indicated on the package.

Active ingredient

Riamilovir

Conditions of release from pharmacies

By prescription

Dosage form

Capsules